Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
about
Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.Drug-induced and drug-dependent immune thrombocytopenias.Argatroban dosing in patients with heparin-induced thrombocytopenia.Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor.Direct thrombin inhibitors: pharmacology and clinical relevance.Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.Review: recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia.Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.Reversible crystallization of argatroban after subcutaneous application in pigs.Evaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia.The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution.Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.[Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].Argatroban for anticoagulation of a blood salvage system - an ex-vivo studyPharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban.Treatment of intracardiac thrombi with argatroban.Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
P2860
Q33336836-EB186A9B-FA70-442D-A223-874AEBCA66D9Q33339739-B821B037-2209-4152-9721-080143DDC505Q33348817-D65A89ED-5E58-4765-85E8-270F89229784Q33365108-1C3ED09C-1E89-48B9-8943-3BCC0CB73F83Q33366516-81EA6FCB-B77A-4630-BC81-7D39CA26ADCCQ33370696-4C219890-C93A-4ADB-B700-9688632C6BF0Q33382275-9C7DA86C-7765-401A-AEF0-56F2F5583745Q33382677-79FCB28A-04A8-43ED-952C-B0B2C84E27ADQ33387783-A463B7E7-9650-4861-9E05-A48B7F173034Q33403263-FDE2CB54-5572-4170-9DDE-144DD653B4CFQ33403381-33896677-4590-4D94-885E-9B32A4D9DBE7Q33409923-AF5748C0-053E-4EB2-821E-1DC0F97DCB30Q33412990-3F991C91-375E-4CCB-8900-3E0B55C0ECDEQ33425409-9E58DBC6-A755-4D05-A56B-0F5CF5B3C2BAQ33437808-08E2ADFA-BA2E-4E4A-A70F-9E43B1FFB01AQ36078286-3F688A07-9269-43FA-AFAA-81DE0D34A777Q45022889-818B9555-AB48-4FE0-8507-080D98F56F88Q45861270-748A8804-81B1-4756-B7AD-B123C85F4CC9Q46416691-717FD703-DE11-4B28-B509-236EEFF27BFDQ53935831-8280888F-1F7C-41EF-B693-4E297086DF45
P2860
Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@en
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@nl
type
label
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@en
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@nl
prefLabel
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@en
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@nl
P2093
P2860
P1433
P1476
Comparison of anticoagulant ef ...... d heparin in healthy subjects.
@en
P2093
J V St Peter
L J Lambrecht
M J Hursting
P2860
P304
P356
10.1592/PHCO.20.9.756.35194
P407
P577
2000-07-01T00:00:00Z